678 related articles for article (PubMed ID: 17623039)
21. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
23. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
24. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
Uversky VN
J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
[TBL] [Abstract][Full Text] [Related]
25. DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes.
Hegde ML; Rao KS
Arch Biochem Biophys; 2007 Aug; 464(1):57-69. PubMed ID: 17537399
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between alpha-synuclein and Parkinson's disease].
Nishioka K; Hattori N
Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
[TBL] [Abstract][Full Text] [Related]
27. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.
Chavarría C; Souza JM
Arch Biochem Biophys; 2013 May; 533(1-2):25-32. PubMed ID: 23454347
[TBL] [Abstract][Full Text] [Related]
28. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment.
Kim HJ; Chatani E; Goto Y; Paik SR
J Microbiol Biotechnol; 2007 Dec; 17(12):2027-32. PubMed ID: 18167451
[TBL] [Abstract][Full Text] [Related]
29. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
[TBL] [Abstract][Full Text] [Related]
30. Studies of the aggregation of an amyloidogenic alpha-synuclein peptide fragment.
Madine J; Doig AJ; Kitmitto A; Middleton DA
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1113-5. PubMed ID: 16246058
[TBL] [Abstract][Full Text] [Related]
31. Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation.
Bertoncini CW; Rasia RM; Lamberto GR; Binolfi A; Zweckstetter M; Griesinger C; Fernandez CO
J Mol Biol; 2007 Sep; 372(3):708-22. PubMed ID: 17681539
[TBL] [Abstract][Full Text] [Related]
32. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
Schnack C; Danzer KM; Hengerer B; Gillardon F
Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
[TBL] [Abstract][Full Text] [Related]
33. [Neurodegenerative conformational disease and its molecular bases].
Li WW; Cai DF; Ren HM
Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
35. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
Halliday GM; McCann H
Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
[TBL] [Abstract][Full Text] [Related]
36. Controversy: is Parkinson's disease a single disease entity? Yes.
Takahashi H; Wakabayashi K
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
[TBL] [Abstract][Full Text] [Related]
37. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
Tavassoly O; Lee JS
FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
[TBL] [Abstract][Full Text] [Related]
38. The role of α-synuclein in neurotransmission and synaptic plasticity.
Cheng F; Vivacqua G; Yu S
J Chem Neuroanat; 2011 Dec; 42(4):242-8. PubMed ID: 21167933
[TBL] [Abstract][Full Text] [Related]
39. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
[TBL] [Abstract][Full Text] [Related]
40. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
